Cygnus Technologies
4332 Southport-Supply Rd SE
Southport
NC
28461
United States
Tel: 619405-1276
8 articles with Cygnus Technologies
-
New Kit Predicts Retroviral Particle Clearance in Biopharmaceutical Manufacturing
11/7/2022
Cygnus Technologies, part of Maravai LifeSciences, the leading assay and services provider for the detection and characterization of process-related impurities in biopharmaceuticals, announced the launch of the MockV® RVLP Kit.
-
Bio-Techne and Cygnus Technologies, Part of Maravai Lifesciences, Introduce New Simple Plex HEK 293 HCP 3G Immunoassay
4/12/2022
Bio-Techne Corporation and Cygnus Technologies, part of Maravai LifeSciences, announced the launch of the Simple Plex™ HEK 293 HCP 3G assay for automated process impurity testing on the Ella™ immunoassay platform.
-
Gyros Protein Technologies and Cygnus Technologies Expand Collaboration to Support Improved Bioprocess Impurity Analytics, and Introduce HEK 293 HCP Assay Reagent Set for Gyrolab
7/7/2021
Collaboration is poised to deliver a range of ready-to-use bioprocess impurity reagent sets optimized for use with the Gyrolab platform
-
Cygnus Technologies Attains ISO 9001:2015 Certification
9/26/2019
Cygnus Technologies, a Maravai LifeSciences company, announced that it has achieved ISO 9001:2015 certification.
-
Bio-Techne And Cygnus Technologies Announce Partnership For 3G CHO-HCP Assay
8/13/2019
Bio-Techne Corporation and Cygnus Technologies, part of Maravai LifeSciences, announced today a strategic partnership for the quantification of Chinese hamster ovary host cell proteins (CHO-HCP) on the ProteinSimple™-branded Ella™ immunoassay platform.
-
Cygnus Technologies Introduces Mass Spec Services for Host Cell Protein Impurity Characterization
6/24/2019
Cygnus Technologies, a Maravai LifeSciences company, announces an expansion of its service offerings for host cell protein (HCP) analysis.
-
New Kit Identifies Endonuclease Impurities in Gene Therapy and Vaccine Development
4/18/2019
Cygnus Technologies, the leading assay and services provider for the detection and characterization of impurities in biopharmaceuticals, introduces the EndonucleaseGTP™ ELISA Kit for the detection and quantitation of residual endonuclease impurities in recombinant vaccines and viral vectors used for gene therapy.
-
Gyros Protein Technologies and Cygnus Technologies Sign Licensing and Supply Agreement
7/10/2018
Gyros Protein Technologies to develop immunoassay kits for biotherapeutic impurity analysis using Cygnus Technologies’ proprietary reagents